SEC Tracker
Get the app

Helus Pharma HELP

Helus Pharma to participate in Guggenheim Healthcare Innovation Conference

Foreign issuer report

Form
6-K
Filed
Importance
Routine
  1. CEO Michael Halstead to participate in a fireside chat on November 9, 2026 at 3:00 p.m. EDT.
  2. Company is a clinical-stage pharmaceutical company focused on mental health treatments.
  3. Developing HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder.

Written from the 6-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Helus Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.

  1. Acura Pharmaceuticals ACUR
  2. Ayala Pharmaceuticals ADXS
  3. Ampio Pharmaceuticals AMPE
  4. Alterity Therapeutics ATHE
  5. Adhera Therapeutics ATRX